In cancer stem cell and animal models, rebecsinib reversed overactive protein splicing of ADAR1 protein that drives cloning capacity and immune evasion by many malignancies.
The Centre has amended the Drugs Rules, 1945 to bring stem cell therapies, gene therapeutics and xenografts under stricter licensing and regulatory oversight.